Ethical AI for rare disease research
By incorporating community engagement and ethics throughout the entire development of a project, multimodal artificial intelligence (MAI) can be more equitably implemented, trusted by the community, and responsive to the community’s needs. With a team of University of Chicago researchers and other stakeholders, we are working on an MAI approach for monogenic epilepsies with the principles of responsible development and community involvement built directly into the work, developing an ethical framework for further MAI research in pediatric rare diseases.

MAI Ethics engagement steps
Led by Alan Liang, Dr. Wim van Drongelen, and Dr. Douglas Nordli, the team’s approach uses AI to draw on information from EEGs together with clinical and genetic data to explore what these signals can reveal about brain function. Community engagement and ethical review are part of the process at every stage, led by a stakeholder engagement panel bringing together the perspectives of families, clinicians, and others close to these conditions. The panel reviews the model’s results and weighs their ethical implications, and that input feeds back into how the model is refined. The underlying research, which will soon be shared on public research repository medRxiv, points toward noninvasive ways to understand monogenic epilepsies and, in time, to assess how new therapies are working.